Cel Sci Corporation (CVM)

[GD]

10-Q: "In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.5 million, of which approximately $6.7 million has been incurred to date. Pursuant to the amendment, the landlord agreed to finance the final $2.4 million of the costs incurred, i.e., after the Company has financed the initial $8.1 million. Per the terms of the financing, upon completion of the project, the $2.4 million will be repaid through increased lease payments over the remaining lease term."

This may prove my point I posted here before that FDA may allow IDMC
to inform CVM the trial may succeed in the final data, which allow
CVM to prepare commercial production in advance of BLA, the question
left to answer is how strong the OS data is, IMO.